<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">35286466</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1420-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>14</Day></PubDate></JournalIssue><Title>Cellular and molecular life sciences : CMLS</Title><ISOAbbreviation>Cell Mol Life Sci</ISOAbbreviation></Journal><ArticleTitle>Insights into the identification of a molecular signature for amyotrophic lateral sclerosis exploiting integrated microRNA profiling of iPSC-derived motor neurons and exosomes.</ArticleTitle><Pagination><StartPage>189</StartPage><MedlinePgn>189</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">189</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00018-022-04217-1</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a rare neurodegenerative disorder characterized by progressive degeneration of motor neurons (MNs). Most cases are sporadic, whereas 10% are familial. The pathological mechanisms underlying the disease are partially understood, but it is increasingly being recognized that alterations in RNA metabolism and deregulation of microRNA (miRNA) expression occur in ALS. In this study, we performed miRNA expression profile analysis of iPSC-derived MNs and related exosomes from familial patients and healthy subjects. We identified dysregulation of miR-34a, miR-335 and miR-625-3p expression in both MNs and exosomes. These miRNAs regulate genes and pathways which correlate with disease pathogenesis, suggesting that studying miRNAs deregulation can contribute to deeply investigate the molecular mechanisms underlying the disease. We also assayed the expression profile of these miRNAs in the cerebrospinal fluid (CSF) of familial (fALS) and sporadic patients (sALS) and we identified a significant dysregulation of miR-34a-3p and miR-625-3p levels in ALS compared to controls. Taken together, all these findings suggest that miRNA analysis simultaneously performed in different human biological samples could represent a promising molecular tool to understand the etiopathogenesis of ALS and to develop new potential miRNA-based strategies in this new propitious therapeutic era.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rizzuti</LastName><ForeName>Mafalda</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurology Unit, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melzi</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurology Unit, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gagliardi</LastName><ForeName>Delia</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Physiopathology and Transplants, Dino Ferrari Center, University of Milan, via Francesco Sforza 35, 20122, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Resnati</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Physiopathology and Transplants, Dino Ferrari Center, University of Milan, via Francesco Sforza 35, 20122, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meneri</LastName><ForeName>Megi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurology Unit, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dioni</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>EPIGET LAB, Unit of Occupational Medicine, Department of Clinical Sciences and Community Health, University of Milan, IRCCS Ca' Granda Foundation Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masrori</LastName><ForeName>Pegah</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Laboratory of Neurobiology, Center for Brain and Disease, KU Leuven, University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Department, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hersmus</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Laboratory of Neurobiology, Center for Brain and Disease, KU Leuven, University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poesen</LastName><ForeName>Koen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Laboratory for Molecular Neurobiomarker Research, Leuven Brain Institute, KU Leuven, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Locatelli</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Physiopathology and Transplants, Dino Ferrari Center, University of Milan, via Francesco Sforza 35, 20122, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biella</LastName><ForeName>Fabio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Physiopathology and Transplants, Dino Ferrari Center, University of Milan, via Francesco Sforza 35, 20122, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silipigni</LastName><ForeName>Rosamaria</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory of Medical Genetics, IRCCS Ca' Granda Foundation Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bollati</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>EPIGET LAB, Unit of Occupational Medicine, Department of Clinical Sciences and Community Health, University of Milan, IRCCS Ca' Granda Foundation Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bresolin</LastName><ForeName>Nereo</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurology Unit, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiopathology and Transplants, Dino Ferrari Center, University of Milan, via Francesco Sforza 35, 20122, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Comi</LastName><ForeName>Giacomo Pietro</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurology Unit, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiopathology and Transplants, Dino Ferrari Center, University of Milan, via Francesco Sforza 35, 20122, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neuromuscular and Rare Diseases Unit, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Laboratory of Neurobiology, Center for Brain and Disease, KU Leuven, University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Department, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nizzardo</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurology Unit, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corti</LastName><ForeName>Stefania</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5734-7476</Identifier><AffiliationInfo><Affiliation>Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurology Unit, Milan, Italy. stefania.corti@unimi.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiopathology and Transplants, Dino Ferrari Center, University of Milan, via Francesco Sforza 35, 20122, Milan, Italy. stefania.corti@unimi.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>smallRNALS</GrantID><Agency>Fondazione Italiana di Ricerca per la SLA, AriSLA</Agency><Country/></Grant><Grant><GrantID>TransALS</GrantID><Agency>Fondazione Regionale per la Ricerca Biomedica, FRRB</Agency><Country/></Grant><Grant><GrantID>Ricerca Corrente 2020 RC245</GrantID><Agency>Italian Ministry of Health</Agency><Country/></Grant><Grant><GrantID>Integrals</GrantID><Agency>E-Rare3 JTC2018</Agency><Country/></Grant><Grant><GrantID>RF-2013-02355764</GrantID><Agency>Italian Ministry of Health</Agency><Country/></Grant><Grant><GrantID>senior clinical investigatorship of FWO-Vlaanderen</GrantID><Agency>The E. von Behring Chair for Neuromuscular and Neurodegenerative Disorders</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cell Mol Life Sci</MedlineTA><NlmUniqueID>9705402</NlmUniqueID><ISSNLinking>1420-682X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C522425">MIRN34 microRNA, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C575476">MIRN625 microRNA, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002450" MajorTopicYN="N">Cell Communication</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055354" MajorTopicYN="N">Exosomes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">CSF</Keyword><Keyword MajorTopicYN="N">Exosomes</Keyword><Keyword MajorTopicYN="N">Motor neurons</Keyword><Keyword MajorTopicYN="N">miRNA</Keyword></KeywordList><CoiStatement>The authors report no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>2</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>14</Day><Hour>17</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35286466</ArticleId><ArticleId IdType="pmc">PMC8921154</ArticleId><ArticleId IdType="doi">10.1007/s00018-022-04217-1</ArticleId><ArticleId IdType="pii">10.1007/s00018-022-04217-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Wobst HJ, Mack KL, Brown DG, et al. The clinical trial landscape in amyotrophic lateral sclerosis&#x2014;past, present, and future. Med Res Rev. 2020;40:1352&#x2013;1384. doi: 10.1002/med.21661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21661</ArticleId><ArticleId IdType="pmc">PMC7417284</ArticleId><ArticleId IdType="pubmed">32043626</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256. doi: 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268. doi: 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, Blair IP, Tripathi VB, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672. doi: 10.1126/science.1154584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1154584</ArticleId><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski TJ, Bosco DA, Leclerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205&#x2013;1208. doi: 10.1126/science.1166066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1166066</ArticleId><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, Rogelj B, Hortob&#xe1;gyi T, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208&#x2013;1211. doi: 10.1126/science.1165942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165942</ArticleId><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol. 2020;27:1918&#x2013;1929. doi: 10.1111/ene.14393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14393</ArticleId><ArticleId IdType="pmc">PMC7540334</ArticleId><ArticleId IdType="pubmed">32526057</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Polymenidou M, Cleveland DW. TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum Mol Genet. 2010;19:R46&#x2013;64. doi: 10.1093/hmg/ddq137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq137</ArticleId><ArticleId IdType="pmc">PMC3167692</ArticleId><ArticleId IdType="pubmed">20400460</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahara Y, Mieda-Sato A. TDP-43 promotes microRNA biogenesis as a component of the drosha and dicer complexes. Proc Natl Acad Sci USA. 2012;109:3347&#x2013;3352. doi: 10.1073/pnas.1112427109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1112427109</ArticleId><ArticleId IdType="pmc">PMC3295278</ArticleId><ArticleId IdType="pubmed">22323604</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A, M&#xfc;ller K, Ludolph AC, Weishaupt JH. Systemic dysregulation of TDP-43 binding microRNAs in amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2013;1:42. doi: 10.1186/2051-5960-1-42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2051-5960-1-42</ArticleId><ArticleId IdType="pmc">PMC3893596</ArticleId><ArticleId IdType="pubmed">24252274</ArticleId></ArticleIdList></Reference><Reference><Citation>Dini Modigliani S, Morlando M, Errichelli L, et al. An ALS-associated mutation in the FUS 3&#x2032;-UTR disrupts a microRNA&#x2013;FUS regulatory circuitry. Nat Commun. 2014;5:4335. doi: 10.1038/ncomms5335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms5335</ArticleId><ArticleId IdType="pubmed">25004804</ArticleId></ArticleIdList></Reference><Reference><Citation>Olejniczak M, Kotowska-Zimmer A, Krzyzosiak W. Stress-induced changes in miRNA biogenesis and functioning. Cell Mol Life Sci. 2018;75:177&#x2013;191. doi: 10.1007/s00018-017-2591-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-017-2591-0</ArticleId><ArticleId IdType="pmc">PMC5756259</ArticleId><ArticleId IdType="pubmed">28717872</ArticleId></ArticleIdList></Reference><Reference><Citation>Capauto D, Colantoni A, Lu L, et al. A regulatory circuitry between Gria2, miR-409, and miR-495 is affected by ALS FUS mutation in ESC-derived motor neurons. Mol Neurobiol. 2018;55:7635&#x2013;7651. doi: 10.1007/s12035-018-0884-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-0884-4</ArticleId><ArticleId IdType="pmc">PMC6132778</ArticleId><ArticleId IdType="pubmed">29430619</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T, Wu YC, Mullane P, et al. FUS regulates activity of microRNA-mediated gene silencing. Mol Cell. 2018;69:787&#x2013;801.e8. doi: 10.1016/j.molcel.2018.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2018.02.001</ArticleId><ArticleId IdType="pmc">PMC5836505</ArticleId><ArticleId IdType="pubmed">29499134</ArticleId></ArticleIdList></Reference><Reference><Citation>Paez-Colasante X, Figueroa-Romero C, Rumora AE, et al. Cytoplasmic TDP43 binds microRNAs: new disease targets in amyotrophic lateral sclerosis. Front Cell Neurosci. 2020;14:117. doi: 10.3389/fncel.2020.00117.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2020.00117</ArticleId><ArticleId IdType="pmc">PMC7235295</ArticleId><ArticleId IdType="pubmed">32477070</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo X, Zhou J, Li Y, et al. TDP-43 aggregation induced by oxidative stress causes global mitochondrial imbalance in ALS. Nat Struct Mol Biol. 2021;28:132&#x2013;142. doi: 10.1038/s41594-020-00537-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41594-020-00537-7</ArticleId><ArticleId IdType="pubmed">33398173</ArticleId></ArticleIdList></Reference><Reference><Citation>Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet. 2011;12:99&#x2013;110. doi: 10.1038/nrg2936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg2936</ArticleId><ArticleId IdType="pubmed">21245828</ArticleId></ArticleIdList></Reference><Reference><Citation>Fineberg SK, Kosik KS, Davidson BL. MicroRNAs potentiate neural development. Neuron. 2009;64:303&#x2013;309. doi: 10.1016/j.neuron.2009.10.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2009.10.020</ArticleId><ArticleId IdType="pubmed">19914179</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowak JS, Michlewski G. miRNAs in development and pathogenesis of the nervous system. Biochem Soc Trans. 2013;41:815&#x2013;820. doi: 10.1042/BST20130044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST20130044</ArticleId><ArticleId IdType="pubmed">23863137</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju&#x17a;wik CA, DrakeZhang SY, et al. microRNA dysregulation in neurodegenerative diseases: a systematic review. Prog Neurobiol. 2019;182:101664. doi: 10.1016/j.pneurobio.2019.101664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2019.101664</ArticleId><ArticleId IdType="pubmed">31356849</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashed MH, Bayraktar E, Helal GK, et al. Exosomes: from garbage bins to promising therapeutic targets. Int J Mol Sci. 2017 doi: 10.3390/ijms18030538.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18030538</ArticleId><ArticleId IdType="pmc">PMC5372554</ArticleId><ArticleId IdType="pubmed">28257101</ArticleId></ArticleIdList></Reference><Reference><Citation>McKelvey KJ, Powell KL, Ashton AW, et al. Exosomes: mechanisms of uptake. J Circ Biomark. 2015;4:7. doi: 10.5772/61186.</Citation><ArticleIdList><ArticleId IdType="doi">10.5772/61186</ArticleId><ArticleId IdType="pmc">PMC5572985</ArticleId><ArticleId IdType="pubmed">28936243</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons M, Raposo G. Exosomes&#x2013;vesicular carriers for intercellular communication. Curr Opin Cell Biol. 2009;21:575&#x2013;581. doi: 10.1016/j.ceb.2009.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ceb.2009.03.007</ArticleId><ArticleId IdType="pubmed">19442504</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakur BK, Zhang H, Becker A, et al. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res. 2014;24:766&#x2013;769. doi: 10.1038/cr.2014.44.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2014.44</ArticleId><ArticleId IdType="pmc">PMC4042169</ArticleId><ArticleId IdType="pubmed">24710597</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardiotis E, Aloizou A-M, Siokas V, et al. The role of MicroRNAs in patients with amyotrophic lateral sclerosis. J Mol Neurosci. 2018;66:617&#x2013;628. doi: 10.1007/s12031-018-1204-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-018-1204-1</ArticleId><ArticleId IdType="pubmed">30415446</ArticleId></ArticleIdList></Reference><Reference><Citation>Emde A, Eitan C, Liou L-L et al (2015) Dysregulated miRNA biogenesis downstream of cellular stress and ALS-causing mutations: a new mechanism for ALS. EMBO J 34:2633&#x2013;2651. 10.15252/embj.201490493</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4641530</ArticleId><ArticleId IdType="pubmed">26330466</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinchetti P, Rizzuti M, Faravelli I, Corti S. MicroRNA metabolism and dysregulation in amyotrophic lateral sclerosis. Mol Neurobiol. 2018;55:2617&#x2013;2630. doi: 10.1007/s12035-017-0537-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-017-0537-z</ArticleId><ArticleId IdType="pubmed">28421535</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao P, Benito E, Fischer A. MicroRNAs as biomarkers for CNS disease. Front Mol Neurosci. 2013;6:39. doi: 10.3389/fnmol.2013.00039.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2013.00039</ArticleId><ArticleId IdType="pmc">PMC3840814</ArticleId><ArticleId IdType="pubmed">24324397</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricci C, Marzocchi C, Battistini S. MicroRNAs as biomarkers in amyotrophic lateral sclerosis. Cells. 2018;7:E219. doi: 10.3390/cells7110219.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells7110219</ArticleId><ArticleId IdType="pmc">PMC6262636</ArticleId><ArticleId IdType="pubmed">30463376</ArticleId></ArticleIdList></Reference><Reference><Citation>Joilin G, Leigh PN, Newbury SF, Hafezparast M (2019) An overview of microRNAs as biomarkers of ALS. Front Neurol 10:186</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6416171</ArticleId><ArticleId IdType="pubmed">30899244</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Zhang L. Circulating exosomal miRNA as diagnostic biomarkers of neurodegenerative diseases. Front Mol Neurosci. 2020;13:53. doi: 10.3389/fnmol.2020.00053.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2020.00053</ArticleId><ArticleId IdType="pmc">PMC7174585</ArticleId><ArticleId IdType="pubmed">32351363</ArticleId></ArticleIdList></Reference><Reference><Citation>Dasgupta I, Chatterjee A. Recent advances in miRNA delivery systems. Methods Protoc. 2021;4:10. doi: 10.3390/mps4010010.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/mps4010010</ArticleId><ArticleId IdType="pmc">PMC7839010</ArticleId><ArticleId IdType="pubmed">33498244</ArticleId></ArticleIdList></Reference><Reference><Citation>Maury Y, C&#xf4;me J, Piskorowski RA, et al. Combinatorial analysis of developmental cues efficiently converts human pluripotent stem cells into multiple neuronal subtypes. Nat Biotechnol. 2015;33:89&#x2013;96. doi: 10.1038/nbt.3049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3049</ArticleId><ArticleId IdType="pubmed">25383599</ArticleId></ArticleIdList></Reference><Reference><Citation>Pergoli L, Cantone L, Favero C, et al. Extracellular vesicle-packaged miRNA release after short-term exposure to particulate matter is associated with increased coagulation. Part Fibre Toxicol. 2017;14:32. doi: 10.1186/s12989-017-0214-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12989-017-0214-4</ArticleId><ArticleId IdType="pmc">PMC5594543</ArticleId><ArticleId IdType="pubmed">28899404</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Siddiqui S, Gabriely G, et al. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest. 2012;122:3063&#x2013;3087. doi: 10.1172/JCI62636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI62636</ArticleId><ArticleId IdType="pmc">PMC3428086</ArticleId><ArticleId IdType="pubmed">22863620</ArticleId></ArticleIdList></Reference><Reference><Citation>Benigni M, Ricci C, Jones AR, et al. Identification of miRNAs as potential biomarkers in cerebrospinal fluid from amyotrophic lateral sclerosis patients. Neuromolecular Med. 2016;18:551&#x2013;560. doi: 10.1007/s12017-016-8396-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12017-016-8396-8</ArticleId><ArticleId IdType="pubmed">27119371</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong X, Zhai J, Yan C, et al. Recent advances in understanding FOXN3 in breast cancer, and other malignancies. Front Oncol. 2019;9:234. doi: 10.3389/fonc.2019.00234.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2019.00234</ArticleId><ArticleId IdType="pmc">PMC6555274</ArticleId><ArticleId IdType="pubmed">31214487</ArticleId></ArticleIdList></Reference><Reference><Citation>Antar LN, Li C, Zhang H, et al. Local functions for FMRP in axon growth cone motility and activity-dependent regulation of filopodia and spine synapses. Mol Cell Neurosci. 2006;32:37&#x2013;48. doi: 10.1016/j.mcn.2006.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2006.02.001</ArticleId><ArticleId IdType="pubmed">16631377</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa-Romero C, Hur J, Bender DE, et al. Identification of epigenetically altered genes in sporadic amyotrophic lateral sclerosis. PLoS ONE. 2012;7:e52672. doi: 10.1371/journal.pone.0052672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0052672</ArticleId><ArticleId IdType="pmc">PMC3530456</ArticleId><ArticleId IdType="pubmed">23300739</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucchia M, Ramirez A, Parente V, et al. Therapeutic development in amyotrophic lateral sclerosis. Clin Ther. 2015;37:668&#x2013;680. doi: 10.1016/j.clinthera.2014.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2014.12.020</ArticleId><ArticleId IdType="pubmed">25666449</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Mazzini L, Mora G. Disease-modifying therapies in amyotrophic lateral sclerosis. Neuropharmacology. 2020;167:107986. doi: 10.1016/j.neuropharm.2020.107986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2020.107986</ArticleId><ArticleId IdType="pubmed">32062193</ArticleId></ArticleIdList></Reference><Reference><Citation>Amado DA, Davidson BL. Gene therapy for ALS: a review. Mol Ther. 2021;29:3345&#x2013;3358. doi: 10.1016/j.ymthe.2021.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2021.04.008</ArticleId><ArticleId IdType="pmc">PMC8636154</ArticleId><ArticleId IdType="pubmed">33839324</ArticleId></ArticleIdList></Reference><Reference><Citation>Allodi I, Comley L, Nichterwitz S, et al. Differential neuronal vulnerability identifies IGF-2 as a protective factor in ALS. Sci Rep. 2016;6:25960. doi: 10.1038/srep25960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep25960</ArticleId><ArticleId IdType="pmc">PMC4867585</ArticleId><ArticleId IdType="pubmed">27180807</ArticleId></ArticleIdList></Reference><Reference><Citation>Laneve P, Tollis P, Caffarelli E. RNA deregulation in amyotrophic lateral sclerosis: the noncoding perspective. Int J Mol Sci. 2021;22:10285. doi: 10.3390/ijms221910285.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms221910285</ArticleId><ArticleId IdType="pmc">PMC8508793</ArticleId><ArticleId IdType="pubmed">34638636</ArticleId></ArticleIdList></Reference><Reference><Citation>Butti Z, Patten SA. RNA dysregulation in amyotrophic lateral sclerosis. Front Genet. 2018;9:712. doi: 10.3389/fgene.2018.00712.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2018.00712</ArticleId><ArticleId IdType="pmc">PMC6349704</ArticleId><ArticleId IdType="pubmed">30723494</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham J, Keon M, Brennan S, Saksena N. Connecting RNA-modifying similarities of TDP-43, FUS, and SOD1 with microRNA dysregulation amidst a renewed network perspective of amyotrophic lateral sclerosis proteinopathy. Int J Mol Sci. 2020;21:E3464. doi: 10.3390/ijms21103464.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21103464</ArticleId><ArticleId IdType="pmc">PMC7278980</ArticleId><ArticleId IdType="pubmed">32422969</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos-Melo D, Droppelmann CA, He Z, et al. Altered microRNA expression profile in amyotrophic lateral sclerosis: a role in the regulation of NFL mRNA levels. Mol Brain. 2013;6:26. doi: 10.1186/1756-6606-6-26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1756-6606-6-26</ArticleId><ArticleId IdType="pmc">PMC3668997</ArticleId><ArticleId IdType="pubmed">23705811</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice B, Annunziata A, Fiorentino G, et al. miR-338-3p is over-expressed in blood, CFS, serum and spinal cord from sporadic amyotrophic lateral sclerosis patients. Neurogenetics. 2014;15:243&#x2013;253. doi: 10.1007/s10048-014-0420-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10048-014-0420-2</ArticleId><ArticleId IdType="pubmed">25130371</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa-Romero C, Hur J, Lunn JS, et al. Expression of microRNAs in human post-mortem amyotrophic lateral sclerosis spinal cords provides insight into disease mechanisms. Mol Cell Neurosci. 2016;71:34&#x2013;45. doi: 10.1016/j.mcn.2015.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2015.12.008</ArticleId><ArticleId IdType="pmc">PMC4761498</ArticleId><ArticleId IdType="pubmed">26704906</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice B, Manfellotto F, Fiorentino G, et al. Wide-ranging analysis of microRNA profiles in sporadic amyotrophic lateral sclerosis using next-generation sequencing. Front Genet. 2018;9:310. doi: 10.3389/fgene.2018.00310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2018.00310</ArticleId><ArticleId IdType="pmc">PMC6102490</ArticleId><ArticleId IdType="pubmed">30154826</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzuti M, Filosa G, Melzi V, et al. MicroRNA expression analysis identifies a subset of downregulated miRNAs in ALS motor neuron progenitors. Sci Rep. 2018;8:10105. doi: 10.1038/s41598-018-28366-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-28366-1</ArticleId><ArticleId IdType="pmc">PMC6031650</ArticleId><ArticleId IdType="pubmed">29973608</ArticleId></ArticleIdList></Reference><Reference><Citation>Helferich AM, Brockmann SJ, Reinders J, et al. Dysregulation of a novel miR-1825/TBCB/TUBA4A pathway in sporadic and familial ALS. Cell Mol Life Sci. 2018;75:4301&#x2013;4319. doi: 10.1007/s00018-018-2873-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-018-2873-1</ArticleId><ArticleId IdType="pubmed">30030593</ArticleId></ArticleIdList></Reference><Reference><Citation>Loffreda A, Nizzardo M, Arosio A, et al. miR-129-5p: a key factor and therapeutic target in amyotrophic lateral sclerosis. Prog Neurobiol. 2020;190:101803. doi: 10.1016/j.pneurobio.2020.101803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2020.101803</ArticleId><ArticleId IdType="pubmed">32335272</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagliardi D, Comi GP, Bresolin N, Corti S. MicroRNAs as regulators of cell death mechanisms in amyotrophic lateral sclerosis. J Cell Mol Med. 2019;23:1647&#x2013;1656. doi: 10.1111/jcmm.13976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.13976</ArticleId><ArticleId IdType="pmc">PMC6378226</ArticleId><ArticleId IdType="pubmed">30614179</ArticleId></ArticleIdList></Reference><Reference><Citation>Vishnoi A, Rani S. MiRNA biogenesis and regulation of diseases: an overview. Methods Mol Biol. 2017;1509:1&#x2013;10. doi: 10.1007/978-1-4939-6524-3_1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-6524-3_1</ArticleId><ArticleId IdType="pubmed">27826912</ArticleId></ArticleIdList></Reference><Reference><Citation>Volonte C, Apolloni S, Parisi C. MicroRNAs: newcomers into the ALS picture. CNS Neurol Disord Drug Targets. 2015;14:194&#x2013;207. doi: 10.2174/1871527314666150116125506.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527314666150116125506</ArticleId><ArticleId IdType="pubmed">25613506</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbari Dilmaghani N, Hussen BM, Nateghinia S, et al. Emerging role of microRNAs in the pathogenesis of amyotrophic lateral sclerosis. Metab Brain Dis. 2021;36:737&#x2013;749. doi: 10.1007/s11011-021-00697-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11011-021-00697-5</ArticleId><ArticleId IdType="pubmed">33604874</ArticleId></ArticleIdList></Reference><Reference><Citation>Agostini M, Tucci P, Steinert JR, et al. microRNA-34a regulates neurite outgrowth, spinal morphology, and function. PNAS. 2011;108:21099&#x2013;21104. doi: 10.1073/pnas.1112063108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1112063108</ArticleId><ArticleId IdType="pmc">PMC3248521</ArticleId><ArticleId IdType="pubmed">22160706</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Liu P, Zhu H, et al. miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer&#x2019;s disease, inhibits bcl2 translation. Brain Res Bull. 2009;80:268&#x2013;273. doi: 10.1016/j.brainresbull.2009.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2009.08.006</ArticleId><ArticleId IdType="pubmed">19683563</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Zhang C, Guan Y, et al. Screening the expression characteristics of several miRNAs in G93A-SOD1 transgenic mouse: altered expression of miRNA-124 is associated with astrocyte differentiation by targeting Sox2 and Sox9. J Neurochem. 2018;145:51&#x2013;67. doi: 10.1111/jnc.14229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.14229</ArticleId><ArticleId IdType="pubmed">28960306</ArticleId></ArticleIdList></Reference><Reference><Citation>Catanesi M, d&#x2019;Angelo M, Tupone MG, et al. MicroRNAs dysregulation and mitochondrial dysfunction in neurodegenerative diseases. Int J Mol Sci. 2020 doi: 10.3390/ijms21175986.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21175986</ArticleId><ArticleId IdType="pmc">PMC7504116</ArticleId><ArticleId IdType="pubmed">32825273</ArticleId></ArticleIdList></Reference><Reference><Citation>De Luna N, Turon-Sans J, Cortes-Vicente E, et al. Downregulation of miR-335-5P in amyotrophic lateral sclerosis can contribute to neuronal mitochondrial dysfunction and apoptosis. Sci Rep. 2020;10:4308. doi: 10.1038/s41598-020-61246-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-61246-1</ArticleId><ArticleId IdType="pmc">PMC7062873</ArticleId><ArticleId IdType="pubmed">32152380</ArticleId></ArticleIdList></Reference><Reference><Citation>Capitano F, Camon J, Licursi V, et al. MicroRNA-335-5p modulates spatial memory and hippocampal synaptic plasticity. Neurobiol Learn Mem. 2017;139:63&#x2013;68. doi: 10.1016/j.nlm.2016.12.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nlm.2016.12.019</ArticleId><ArticleId IdType="pubmed">28039088</ArticleId></ArticleIdList></Reference><Reference><Citation>You Y, Ikezu T. Emerging roles of extracellular vesicles in neurodegenerative disorders. Neurobiol Dis. 2019;130:104512. doi: 10.1016/j.nbd.2019.104512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.104512</ArticleId><ArticleId IdType="pmc">PMC6689424</ArticleId><ArticleId IdType="pubmed">31229685</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding X-M, Zhao L-J, Qiao H-Y, et al. Long non-coding RNA-p21 regulates MPP+-induced neuronal injury by targeting miR-625 and derepressing TRPM2 in SH-SY5Y cells. Chem Biol Interact. 2019;307:73&#x2013;81. doi: 10.1016/j.cbi.2019.04.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbi.2019.04.017</ArticleId><ArticleId IdType="pubmed">31004593</ArticleId></ArticleIdList></Reference><Reference><Citation>Malko P, Syed Mortadza SA, McWilliam J, Jiang L-H. TRPM2 channel in microglia as a new player in neuroinflammation associated with a spectrum of central nervous system pathologies. Front Pharmacol. 2019;10:239. doi: 10.3389/fphar.2019.00239.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2019.00239</ArticleId><ArticleId IdType="pmc">PMC6423084</ArticleId><ArticleId IdType="pubmed">30914955</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovanda A, Leonardis L, Zidar J, et al. Differential expression of microRNAs and other small RNAs in muscle tissue of patients with ALS and healthy age-matched controls. Sci Rep. 2018;8:5609. doi: 10.1038/s41598-018-23139-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-23139-2</ArticleId><ArticleId IdType="pmc">PMC5884852</ArticleId><ArticleId IdType="pubmed">29618798</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in 12 body fluids. Clin Chem. 2010;56:1733&#x2013;1741. doi: 10.1373/clinchem.2010.147405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2010.147405</ArticleId><ArticleId IdType="pmc">PMC4846276</ArticleId><ArticleId IdType="pubmed">20847327</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice B, Guida M, Guida M, et al. A miRNA signature in leukocytes from sporadic amyotrophic lateral sclerosis. Gene. 2012;508:35&#x2013;40. doi: 10.1016/j.gene.2012.07.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2012.07.058</ArticleId><ArticleId IdType="pubmed">22903028</ArticleId></ArticleIdList></Reference><Reference><Citation>Cloutier F, Marrero A, O&#x2019;Connell C, Morin PJ. MicroRNAs as potential circulating biomarkers for amyotrophic lateral sclerosis. J Mol Neurosci. 2015;56:102&#x2013;112. doi: 10.1007/s12031-014-0471-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-014-0471-8</ArticleId><ArticleId IdType="pubmed">25433762</ArticleId></ArticleIdList></Reference><Reference><Citation>Waller R, Wyles M, Heath PR, et al. Small RNA sequencing of sporadic amyotrophic lateral sclerosis cerebrospinal fluid reveals differentially expressed miRNAs related to neural and glial activity. Front Neurosci. 2017;11:731. doi: 10.3389/fnins.2017.00731.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2017.00731</ArticleId><ArticleId IdType="pmc">PMC5767269</ArticleId><ArticleId IdType="pubmed">29375285</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheinerman KS, Toledo JB, Tsivinsky VG, et al. Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases. Alzheimers Res Ther. 2017;9:89. doi: 10.1186/s13195-017-0316-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-017-0316-0</ArticleId><ArticleId IdType="pmc">PMC5679501</ArticleId><ArticleId IdType="pubmed">29121998</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>